Core Insights - UnitedHealth Group has sold its last remaining business in South America, Banmedica, to Patria Investments for $1 billion [2] - The company has been exiting Latin America since 2022, with Banmedica being the final asset after previous sales in Brazil and Peru [3] - The exit from South America is part of CEO Stephen Hemsley's strategy to refocus the business [4] Financial Performance - UnitedHealth raised its annual profit forecast in October and anticipates growth to return in 2026, with momentum expected to build in 2027 [5] - The company incurred an $8.3 billion loss related to its South American exits, with $7.1 billion attributed to Brazil and $1.2 billion linked to Banmedica [5] Business Operations - Banmedica served approximately 1.7 million health insurance members and operated seven hospitals and 47 medical centers prior to the sale [4] - UnitedHealth operates primarily through two units: UnitedHealthcare and Optum, which encompass insurance, care delivery, data, and health services [6]

Core Insights - UnitedHealth Group has agreed to sell its remaining South American business, Banmedica, to Brazilian private equity firm Patria Investments for approximately $1 billion [1] - The deal was signed last Saturday and is expected to be officially announced this week [1] - UnitedHealth has been exiting the Latin American market since 2022, having previously sold its operations in Brazil and Peru [1] Company Strategy - The sale of Banmedica, which operates in Colombia and Chile, has been under negotiation for nearly a year [1] - As of June this year, Banmedica had 1.7 million health insurance members, 7 hospitals, and 47 medical centers [1] - The exit from the region aligns with UnitedHealth's efforts under CEO Stephen Hemsley to reduce distractions and refocus on core operations [1] Financial Impact - UnitedHealth reported a loss of $8.3 billion last year due to the sale of its South American operations, with $7.1 billion attributed to exiting the Brazilian market and $1.2 billion from the Banmedica business [1] - The company raised its annual profit forecast in October and expects to return to growth by 2026 [1]

Core Insights - UnitedHealth Group has agreed to sell its last business in South America, Banmedica, to Brazilian private equity firm Patria Investments for $1 billion [1] - The final agreement was signed on Saturday and is expected to be announced on Monday [1] - UnitedHealth has been attempting to exit the Latin American market since 2022, having already sold its operations in Brazil and Peru [1] - The sale of Banmedica, which operates in Colombia and Chile, has been under discussion for nearly a year [1]

Core Insights - UnitedHealth Group has agreed to sell its last South American business, Banmedica, to Brazilian private equity group Patria Investments for $1 billion [1] Company Summary - The sale of Banmedica marks the exit of UnitedHealth Group from the South American market, indicating a strategic shift in its business operations [1] - The transaction is valued at $1 billion, reflecting the company's efforts to streamline its portfolio and focus on core markets [1] Industry Summary - The involvement of Patria Investments highlights the growing interest of private equity firms in the healthcare sector in South America [1] - This transaction may signal further consolidation in the healthcare industry within the region as companies seek to optimize their operations and investments [1]

Core Insights - The company has released its latest top investment picks for November 2025, emphasizing the timeliness of joining to access these opportunities [1] - The company invests significant resources, over $100,000 annually, into researching profitable investment opportunities to provide high-yield strategies [1] Member Satisfaction - The company's approach has garnered over 190 five-star reviews from satisfied members, indicating a positive reception and effectiveness of their strategies [2] - Members are encouraged to join now to start maximizing their returns, highlighting the potential benefits of membership [2]

Fundraising - Patria Investments secured $2.9 billion to invest in Latin American infrastructure [1] - This represents Patria Investments' largest fundraising effort for the infrastructure asset class [1] Investment Focus - The raised capital will be allocated to infrastructure projects within Latin America [1]

Group 1 - UnitedHealth Group is accelerating its exit from the Latin American market, having received four non-binding offers for its Banmedica operations in Chile and Colombia, with a transaction value of approximately $1 billion [1] - The company has incurred over $8 billion in losses from its Latin American operations since initiating its exit plan in 2022, primarily due to ongoing losses from its Brazilian subsidiary, Amil, which led to a $7.1 billion impairment loss last year [1] - The new CEO, Steve Hemsley, faces significant pressure as the company's stock price plummeted 25.5% in May and has fallen 40% year-to-date, compounded by an ongoing criminal fraud investigation related to the previous CEO's management [1][2] Group 2 - The Banmedica asset has significantly depreciated since its acquisition, with insurance plan members decreasing from 2.1 million to 1.7 million and the hospital network shrinking from 13 to 7 facilities [2] - UnitedHealth Group acquired Banmedica at a high valuation of 12 times EBITDA in 2018, but continuous losses in Brazil forced the company to withdraw from the country entirely in 2023 [2] - The sale of Banmedica, advised by Brazilian investment bank BTG Pactual, is seen as a critical test for the new CEO's crisis management capabilities amid management turmoil and performance challenges [2]

Financial Data and Key Metrics Changes - Fundraising in Q1 2025 reached a record $3.2 billion, contributing to a target of $6 billion for the year [6][24] - Fee-related earnings (FRE) were $42.6 million or $0.27 per share, reflecting a 2116% year-over-year growth [6][8] - Assets under management (AUM) grew to $46 billion, a 43% increase year-over-year and over 9% sequentially [10][26] - Distributable earnings were $37 million or $0.23 per share, up 12% year-over-year [8][32] Business Line Data and Key Metrics Changes - Fee-earning AUM increased to $35 billion, a 46% year-over-year growth and 6% sequentially [10][28] - Organic net inflows into fee-earning AUM were over $700 million, representing an annualized organic growth rate of over 8.6% [7][26] - Management fee revenue for Q1 was $77.3 million, up 28% year-over-year, but down 17% sequentially due to seasonal factors [28][29] Market Data and Key Metrics Changes - Approximately 20% of fee-earning AUM were in permanent capital vehicles, which is a key long-term objective [13][22] - Strong demand from Asian sovereign wealth fund investors led to $1 billion in commitments during the quarter [14][15] - Local investors accounted for approximately 17% of fundraising in Q1 2025, indicating a growing interest in alternative investments [22] Company Strategy and Development Direction - The company aims to diversify its investment strategies and product offerings, enhancing resilience against global uncertainties [23][24] - The focus is on organic growth through customized investment accounts and special managed accounts, moving away from a product-centric model [6][12] - The company is positioned to benefit from geopolitical shifts, with a low exposure to U.S. tariffs and a focus on local consumption markets in Latin America [17][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the $6 billion fundraising target despite global uncertainties [24][31] - The company believes Latin America is becoming a more attractive destination for capital, benefiting from low geopolitical risks and strong local consumption [18][39] - Management anticipates that the ongoing trade conflicts may lead to increased foreign direct investment (FDI) in the region [42] Other Important Information - The company has a net debt of approximately $143 million, with a net debt to FRE ratio well below one time [32] - The effective tax rate for the quarter was 9.2%, with expectations to trend towards 10% by 2027 [32] - A quarterly dividend of $0.15 per share was approved for 2025, with intentions to repurchase shares throughout the year [33] Q&A Session Summary Question: How are portfolios positioned regarding higher tariffs in the U.S.? - Management indicated that most investments are Latin America-oriented, with minimal exposure to Mexico, and sectors are resilient and locally driven [37][39] Question: Could Chinese institutions divert allocations from U.S. to LatAm? - Management confirmed that there is increased interest from Asian investors, with significant commitments already made [43][45] Question: Is there potential upside to the $6 billion fundraising target? - Management maintained the $6 billion target but acknowledged the strong start with $3.2 billion raised in Q1 [52][54] Question: Update on integration of M&A completed last year? - Management reported that 2025 is focused on integration, with no major issues encountered and synergies expected to improve margins [70][74] Question: Overview of the $3.5 billion pending fee AUM? - Management stated that most pending AUM will be allocated to infrastructure and GPMS verticals, with an average management fee of 96 basis points expected [78][80]